ValuEngine Lowers Pivot Pharmaceuticals (PVOTF) to Sell
ValuEngine downgraded shares of Pivot Pharmaceuticals (OTCMKTS:PVOTF) from a hold rating to a sell rating in a research note released on Friday morning.
Pivot Pharmaceuticals (PVOTF) opened at $0.59 on Friday. Pivot Pharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.65.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/12/05/valuengine-lowers-pivot-pharmaceuticals-pvotf-to-sell.html.
About Pivot Pharmaceuticals
Pivot Pharmaceuticals Inc, formerly Neurokine Pharmaceuticals Inc, is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. The Company is in the business of developing and commercializing new uses for existing prescription drugs, as well as developing encapsulation technology in the treatment of neurodegenerative diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pivot Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivot Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.